Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Clinical impact of ATM and TP53 mutations in mantle cell lymphoma

Jitka Malčíková • 21 Sep 2019
iwCLL 2019
Lymphoma Mantle Cell Lymphoma

Jitka Malčíková, PhD, Masaryk University, Brno, Czech Republic, talks about a paper recently published in Leukemia & Lymphoma on ataxia-telangiectasia mutated (ATM) and TP53 mutations in mantle cell lymphoma. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Jitka Malčíková

1:51
Minor-clone mutations in CLL patients entering first-line treatment
Jitka Malčíková • 21 Sep 2019
2:36
Current knowledge of the TP53 mutation and its role in CLL
Jitka Malčíková • 25 Oct 2018

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals